以吉非替尼, 厄洛替尼为代表的表皮生长因子受体酪氨酸激酶抑制剂(EGFR-TKI)
广泛用于非小细胞肺癌的治疗. 但随着EGFR-TKI 的不断应用, 肿瘤细胞对药物的敏感性逐渐 …

Résumé Objectif Pendant les chirurgies du cancer, l'inflammation médiée par les
prostaglandines pourrait favoriser et activer une maladie micrométastatique avec une …

As things stand in 2023, metastatic osteosarcoma commonly results in death. There has
been little treatment progress in recent decades. To redress the poor prognosis of metastatic …

G-protein–coupled receptors (GPCR) activate the epidermal growth factor receptor (EGFR)
and mediate EGFR-independent signaling pathways to promote the growth of a variety of …

BACKGROUND. Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR‐TKIs)
have demonstrated clinical benefit in patients with nonsmall cell lung cancer (NSCLC) …

A systematic literature review was conducted to determine the incidence and mortality of QT
interval prolongation (QTp), torsades de pointes (TdP), and heart failure (HF) in patients with …

Celecoxib, also known as Celebrex (approved by FDA in 1998) and remembered as the
fastest-selling drug in history, was used as a cyclooxygenase-2 (COX-2) selective inhibitor …

Previous studies suggest that cyclooxygenase-2 (COX-2) expression may predict survival
among patients with non-small cell lung cancer. COX-2 may interact with epidermal growth …

Ultrahigh-resolution optical coherence tomography (UR-OCT) has been used for the first
time to our knowledge to study single-cell basal cell carcinoma (BCC) in vitro. This …

Hypoxia-inducible factor (HIF) accumulates when tumors grow under hypoxic conditions.
The genesis of tumors, however, usually involves normoxic conditions. In this study, we were …